Bier B, Douglas-Jones A, Tötsch M, Dockhorn-Dworniczak B, Böcker W, Jasani B, Schmid K W
Department of Pathology, University of Münster/Westfalia, FRG.
Breast Cancer Res Treat. 1994;30(3):213-21. doi: 10.1007/BF00665963.
Metallothioneins (MTs) are a set of low molecular weight proteins with a high binding affinity to metal ions. MT over-expression has been recently demonstrated in invasive ductal carcinoma of the breast with poor clinical prognosis. In the present study, MTs have been immunohistochemically investigated in normal human breast tissue and a variety of benign, pre-invasive, and malignant breast lesions. In normal breast tissue, MTs were present in myoepithelial cells whereas the vast majority of luminal cells were MT negative. In lesions without increased cancer risk (adenosis and scleradenosis), MT was only immunolocalized in myoepithelial cells. In papillomas, MT was also found exclusively in myoepithelial cells. In most cases of epitheliosis, both the luminal and myoepithelial cells expressed MT. Atypical lobular hyperplasia, lobular carcinoma in situ, and 13/15 invasive lobular carcinomas showed no MT over-expression. The two invasive lobular carcinomas with MT over-expression were classified as pleomorphic lobular carcinomas with apocrine differentiation. In contrast to lobular cancerization, 12/24 ductal in situ carcinomas and 9/20 invasive ductal carcinomas showed MT over-expression. In situ components found within invasive ductal carcinomas usually reflected the MT status of their invasive counterpart. It is concluded from our immunohistochemical results that breast carcinoma cases with MT overexpression arise from lesions which also show MT overexpression. Thus MT expression in carcinomas may be regarded as a genuine feature of the tumour cells and seems not to be related to endogenous or exogenous factors known to induce MT synthesis.
金属硫蛋白(MTs)是一组对金属离子具有高结合亲和力的低分子量蛋白质。最近已证实在临床预后较差的乳腺浸润性导管癌中MT过度表达。在本研究中,已采用免疫组织化学方法对正常人类乳腺组织以及各种良性、癌前和恶性乳腺病变中的MTs进行了研究。在正常乳腺组织中,MTs存在于肌上皮细胞中,而绝大多数管腔细胞MT呈阴性。在无癌症风险增加的病变(腺病和硬化性腺病)中,MT仅免疫定位在肌上皮细胞中。在乳头状瘤中,MT也仅在肌上皮细胞中发现。在大多数上皮组织增生病例中,管腔细胞和肌上皮细胞均表达MT。非典型小叶增生、小叶原位癌以及15例浸润性小叶癌中的13例未显示MT过度表达。2例MT过度表达的浸润性小叶癌被归类为具有大汗腺分化的多形性小叶癌。与小叶癌化不同,24例导管原位癌中的12例以及20例浸润性导管癌中的9例显示MT过度表达。浸润性导管癌中发现的原位成分通常反映其浸润对应物的MT状态。从我们的免疫组织化学结果可以得出结论,MT过度表达的乳腺癌病例起源于也显示MT过度表达的病变。因此,癌组织中的MT表达可能被视为肿瘤细胞的一个真正特征,似乎与已知诱导MT合成的内源性或外源性因素无关。